 |
7 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- || TRC 150094 / Torrent Pharma
Review, Journal: 3,5-T2-an Endogenous Thyroid Hormone Metabolite as Promising Lead Substance in Anti-Steatotic Drug Development? (Pubmed Central) - Jul 29, 2022
Various high fat diet animal models with distinct thyroid hormone status indicate species- and dose-dependent efficiency of 3,5-T2 and its synthetic analogue TRC150094. No convincing evidence has been presented for their clinical use in the prevention or treatment of obesity and related metabolic conditions.
- || TRC 150094 / Torrent Pharma
Clinical, P2 data: TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial. (Pubmed Central) - Mar 5, 2022
Trial registration number: CTRI/2013/03/003444. Date of registration: 4th March 2013.
- || TRC 150094 / Torrent Pharma
Clinical, P1 data, PK/PD data, Journal: Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial. (Pubmed Central) - Oct 5, 2021
Overall, TRC150094 ensured safety and exhibited suitability for all subjects. Clinical Trial Registration: EUDRA CT: 2009-014941-10 (SAD) and CTR-India registration: CTRI/2009/091/000601 (MAD).
- |||| omzotirome (TRC 150094) / Torrent Pharma
Trial completion date, Trial primary completion date: Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension (clinicaltrials.gov) - Jul 17, 2020
P3, N=1250, Recruiting, Sponsor: Torrent Pharmaceuticals Limited
Clinical Trial Registration: EUDRA CT: 2009-014941-10 (SAD) and CTR-India registration: CTRI/2009/091/000601 (MAD). Trial completion date: Aug 2020 --> Aug 2022 | Trial primary completion date: Apr 2020 --> Apr 2022
- |||||| omzotirome (TRC 150094) / Torrent Pharma
Enrollment open: Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension (clinicaltrials.gov) - Mar 15, 2018
P3, N=1250, Recruiting, Sponsor: Torrent Pharmaceuticals Limited
Trial completion date: Aug 2020 --> Aug 2022 | Trial primary completion date: Apr 2020 --> Apr 2022 Not yet recruiting --> Recruiting
- ||||| omzotirome (TRC 150094) / Torrent Pharma
Trial initiation date: Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension (clinicaltrials.gov) - Jan 8, 2018
P3, N=1250, Not yet recruiting, Sponsor: Torrent Pharmaceuticals Limited
Not yet recruiting --> Recruiting Initiation date: Dec 2017 --> Apr 2018
- |||||||||| omzotirome (TRC 150094) / Torrent Pharma
New P3 trial: Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension (clinicaltrials.gov) - Aug 18, 2017
P3, N=1250, Not yet recruiting, Sponsor: Torrent Pharmaceuticals Limited
- | omzotirome (TRC 150094) / Torrent Pharma
Trial completion: Hyperinsulinemic Euglycemic Clamp Protocol (clinicaltrials.gov) - Jul 5, 2012
P2a, N=40, Completed, Sponsor: Torrent Pharmaceuticals Limited
Initiation date: Dec 2017 --> Apr 2018 Not yet recruiting --> Completed